With schizophrenia drug results, Alkermes gets much-needed good news. Insurers could pose a challenge. STAT Plus

• With schizophrenia drug results, Alkermes gets much-needed good news. Insurers could pose a challenge. STAT Plus

Good morning! Andrew Joseph here filling in for Megan for one more day. She'll be back with you Monday. 

With schizophrenia drug results, Alkermes gets much-needed good news. But insurers could pose challenge

By ADAM FEUERSTEIN @adamfeuerstein

NOVEMBER 29, 2018